Notably, the combination of PD-1/PD-L1 inhibitors with CT was associated with an elevated risk of any grade thrombocytopenia and vomiting, while it mitigated the risk of urinary tract infection relative to CT alone or plus placebo. This evidence concerns the gene PDCD1 and urinary tract infection.